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(36.0 ± 16.6%) as compared to peripheral blood mononuclear cells from 21 healty volunteers (5.2 ± 2.0%; p<0.0001). In comparison to AML patients with normal chromosome count, the extent of numerical and structural centrosome aberrations was higher in patients with numerical chromosome changes (50.5 ± 14.2% vs 34.3 ± 12.2%; p<0.0001). When the frequency of centrosome aberrations was analyzed within cytogenetical defined risk groups, we found a correlation of the extent of centrosome abnormalities to all three risk groups (p=0.0015), defined as favorable (22.5 ± 7.3%), intermediate (35.3 ± 13.1%) and adverse (50.3 ± 15.6%). These results indicate that centrosome defects may contribute to the aquisition of chromosome aberrations and thereby to the prognosis in AML.
For personal use only. on . by guest www.bloodjournal.org From
INTRODUCTION
Genetic instability is a common feature in acute myeloid leukemia (AML). Balanced chromosomal translocations such as t (15;17) , t(8;21) and inv(16)/t(16;16) lead to leukemiaspecific fusion-transcripts without gain or loss of genetic material whereas unbalanced chromosome abnormalities result in gains and losses of whole chromosomes or parts thereof (1, 2) . In AML, both numerical and structural chromosome aberrations have been shown to provide information about the clinical course. In large AML clinical trials, especially numerical chromosome aberrations like losses of chromosomes 5 and 7 as well as complex aberrations were identified as adverse prognostic factors for survival. Defects in chromosome number are thought to occur through missegregation of chromosomes (3), but the mechanism by which this occurs has not been elucidated. There are many potential mitotic targets, which could cause unequal segregation of chromosomes, among those chromosomal, spindle microtubule, and centrosomal defects (4). Recently, centrosome aberrations have been described as a possible cause of numerical chromosome abnormalities in many human tumors (5) (6) (7) (8) (9) (10) (11) (12) (13) . As the primary microtubule organizing center of most eukaryotic cells, the centrosome assures symmetry and bipolarity of the cell division process, a function that is essential for accurate chromosome segregation (4).
To investigate whether centrosome aberrations do occur in AML and correlate with cytogenetically defined subgroups, we examined a set of 51 patients with AML using a centrosome-specific antibody to pericentrin (14) . Calculation of centrosome aberrations. Immunostaining of centrosomes was judged satisfactory when the characteristic single or paired centrosome pattern was detected in negative controls. Centrosomes were considered structurally abnormal if they had a diameter at least twice that of centrosomes in nonmalignant control cells and numerically abnormal if they were present in numbers > 2 as described previously (11) . At least 200 consecutive cells per sample were carefully examined. 
RESULTS AND DISCUSSION
To investigate whether centrosome aberrations do occur in AML and correlate with cytogenetically defined subgroups, we examined a set of 51 patients with AML using indirect immunofluorescence with an antibody to pericentrin. Our data set consisted of 30 peripheral blood and 21 bone marrow samples obtained from AML patients at the time of diagnosis (n=41) or at relapse (n=10). In particular, there were 27 males and 24 females with a median age of 60 years (range, 18 -80). A total number of 33 patients were registered as having de novo AML, while 18 patients with secondary AML were analyzed. Cytogenetic information was available for 48 of 51 patients. The karyotype classification was similar to that used in other series (1, 2) . Analogous to the MRC AML 10 trial, all AML patients with a specific abnormality were considered, irrespective of the presence of additional or secondary cytogenetic changes (1).
To determine whether blasts from AML patients harbor abnormal centrosomes, we 
Consequently, the commonly observed abrogation of the p53 and Rb pathways in human malignancies including AML will not only facilitate progression towards DNA replication, but may also deregulate the centrosome duplication cycle (4, 23, 24) . Trial as shown in Table 1 . We found a statistically significant correlation of the extent of centrosome abnormalities to all three risk groups (p=0.0015), defined as favorable (22.5 ± 7.3%), intermediate (35.3 ± 13.1%) and adverse (50.3 ± 15.6%). This difference was mainly due to structural rather than numerical centrosome aberrations, fitting nicely to the ultrastructural observation that in human breast cancers anaplastic morphology and abnormal mitoses correlate to excess pericentriolar material rather than to an increase in centriole or centrosome numbers (25) . The description of p53 and Rb pathway alterations in AML patients with an inferior prognosis and unfavorable cytogenetics further suggests a pathophysiological link to the induction of centrosome aberrations (23, 24) .
In conclusion, our results indicate that centrosome defects are a common feature of AML and suggest that they may contribute to the aquisition of an increasing karyotypic instability.
Since the extent of centrosome abnormalities correlates to cytogenetically defined risk groups in AML, the prognostic importance of centrosome patterns should be studied in prospective trials.
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